From Fierce Biotech
Alnylam also has early research on the second drug mentioned below. ALN-AC3 and ALN-ANG are not in trials yet.
A few weeks after the FDA slapped a clinical hold on GlaxoSmithKline’s late-stage work on an experimental drug for a rare cardiac condition, the pharma giant has decided to put its plans for a Phase III on a back burner. And in a call with analysts, its development partners at Ionis Pharmaceuticals say those safety issues are related to severe declines in platelets — thrombocytopenia— which also recently appeared unexpectedly among some of the patients enrolled in a separate, late-stage study for another drug called volanesorsen.